Author + information
- Pawel Gasior1,
- Marek Gierlotka2,
- Krzysztof Szuczrek-Katanski3,
- Marcin Osuch3,
- Roman Gnot3,
- Agata Dydon3,
- Michal Hawranek4,
- Andrzej Lekston4,
- Mariusz Gasior4 and
- Lech Poloński4
- 13rd Department of Cardiology, Medical University of Silesia, Katowice, Poland
- 23rd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Zabrze, Poland
- 3Scanmed, Gliwice, Poland
- 43rd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland
Presence of durable polymers may be associated with late/very late stent thrombosis occurrence and the need for prolonged dual antiplatelet therapy. Bioabsorbable polymers may facilitate stent healing, thus enhancing clinical safety. We sought to determine the 1-year clinical follow-up in patients treated with the thin strut (71um) bioabsorbable polymer-coated sirolimus-eluting (BP-SES) stent versus durable coating everolimus eluting stent (DP-EES) in daily clinical routine.
Interventional Cardiology Network Registry is a multicenter, all-comers registry of 21 400 consecutive patients treated with primary PCI since 2010. We analyzed 4670 patients treated with either a BP-SES (ALEX™, Balton, Poland) or durable polymer coated (XIENCE™, Abbott, USA) with available one year clinical follow-up using propensity-score matching. Outcomes included target vessel revascularization (TVR) as efficacy outcome and all cause death, myocardial infarction, and definite/probable stent thrombosis as safety outcomes.
After propensity score matching 1649 patients treated with BP-SES and 1649 patients treated with DP-EES were selected. Procedural and clinical characteristics were similar between both groups with. There was no significant difference between tested groups in in-hospital mortality. One year follow-up demonstrated comparable efficacy outcome TVR (BP-SES 5.9% vs. DP-EES 4.6% p=0.10), as well as comparable safety outcomes of all cause death (BP-SES 6.0% vs. DP-EES 5.4% p=0.45), myocardial infarction (BP-SES 6.0% vs. DP-EES 5.4% p=0.45) and definite/probable stent thrombosis (BP-SES 1.46% vs. DP-EES 1.21%; p=0.55).
In this multicenter propensity matched registry, the thin strut biodegradable polymer coated sirolimus-eluting stent demonstrated comparable clinical outcomes at 1-year after implantation to the durable polymer coated everolimus-eluting stent. These data support the relative safety and efficacy of BP-SES in a broad range of patients undergoing percutaneous coronary intervention.
CORONARY: Stents: Drug-Eluting